Other News To Note

• Cell Therapeutics Inc., of Seattle, said its board approved certain amendments to the firm's existing shareholder rights plan to decrease the exercise price of the preferred stock purchase rights from $14 to $8 and to extend the final expiration date from the close of business on the third anniversary of Jan. 7, 2010, to the close of business on Dec. 3, 2015.